Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Bridgebio Pharma Inc (BBIO)

Bridgebio Pharma Inc (BBIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,856,418
  • Shares Outstanding, K 148,956
  • Annual Sales, $ 8,250 K
  • Annual Income, $ -448,720 K
  • 60-Month Beta 0.96
  • Price/Sales 1,298.51
  • Price/Cash Flow N/A
  • Price/Book 81.63
Trade BBIO with:

Options Overview

Details
  • Implied Volatility 71.69%
  • Historical Volatility 60.21%
  • IV Percentile 58%
  • IV Rank 26.40%
  • IV High 144.61% on 03/18/20
  • IV Low 45.53% on 12/10/20
  • Put/Call Vol Ratio 0.93
  • Today's Volume 114
  • Volume Avg (30-Day) 277
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 2,289
  • Open Int (30-Day) 3,118

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -0.87
  • Number of Estimates 6
  • High Estimate -0.70
  • Low Estimate -1.01
  • Prior Year -0.78
  • Growth Rate Est. (year over year) -11.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
62.02 +4.00%
on 02/18/21
73.50 -12.24%
on 02/09/21
+1.52 (+2.41%)
since 02/03/21
3-Month
50.67 +27.29%
on 12/04/20
73.50 -12.24%
on 02/09/21
+13.99 (+27.70%)
since 12/03/20
52-Week
14.23 +353.27%
on 03/18/20
73.50 -12.24%
on 02/09/21
+31.91 (+97.91%)
since 03/03/20

Most Recent Stories

More News
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on March 1, 2021, the compensation committee of BridgeBio's board of...

BBIO : 64.75 (-2.15%)
BridgeBio Pharma and Affiliate Origin Biosciences Announce FDA Approval of NULIBRY(TM) (fosdenopterin), the First and Only Approved Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A

Molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening genetic disorder that progresses rapidly, results in severe and largely irreversible neurological injury, and has a high infant...

BBIO : 64.75 (-2.15%)
Is a Surprise Coming for BridgeBio Pharma (BBIO) This Earnings Season?

BridgeBio Pharma (BBIO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

BBIO : 64.75 (-2.15%)
BridgeBio Pharma (BBIO) Reports Q4 Loss, Misses Revenue Estimates

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -17.44% and -99.21%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

BBIO : 64.75 (-2.15%)
BridgeBio Pharma: 4Q Earnings Snapshot

PALO ALTO, Calif. (AP) _ BridgeBio Pharma Inc. (BBIO) on Thursday reported a loss of $120 million in its fourth quarter.

BBIO : 64.75 (-2.15%)
BridgeBio Pharma, Inc. Reports Fourth Quarter And Full Year 2020 Financial Results And Business Update

-Completed acquisition of Eidos Therapeutics, allowing BridgeBio to deploy its full clinical and commercial infrastructure to develop and plan for potential global commercialization upon regulatory approval...

BBIO : 64.75 (-2.15%)
EIDX : 122.21 (-4.85%)
BridgeBio Pharma To Announce Proof-Of-Concept Data from ADH1 at the Endocrine Society's 2021 Annual Meeting

BridgeBio Pharma, Inc. (Nasdaq: BBIO),�?�a clinical-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers...

BBIO : 64.75 (-2.15%)
Analysts Estimate BridgeBio Pharma (BBIO) to Report a Decline in Earnings: What to Look Out for

BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BBIO : 64.75 (-2.15%)
Stocks Still Near All-Time Highs Despite Sluggish Week

Stocks Still Near All-Time Highs Despite Sluggish Week

NUS : 51.05 (-1.18%)
BBIO : 64.75 (-2.15%)
MCFT : 28.54 (+0.46%)
MNKD : 3.66 (-3.17%)
TVTX : 27.99 (-4.11%)
AIMC : 61.32 (+0.79%)
FISV : 115.78 (+0.09%)
BTG : 4.36 (-3.96%)
AAWW : 58.00 (+2.53%)
BridgeBio Pharma and Affiliate ML Bio Solutions Announce Dosing of First Patient in Phase 2 Trial of BBP-418 in Limb Girdle Muscular Dystrophy Type 2i (LGMD2i)

BridgeBio Pharma, Inc. (Nasdaq: BBIO),�?�a clinical-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers...

BBIO : 64.75 (-2.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United...

See More

Key Turning Points

3rd Resistance Point 74.36
2nd Resistance Point 72.68
1st Resistance Point 69.43
Last Price 64.75
1st Support Level 64.50
2nd Support Level 62.82
3rd Support Level 59.57

See More

52-Week High 73.50
Last Price 64.75
Fibonacci 61.8% 50.86
Fibonacci 50% 43.86
Fibonacci 38.2% 36.87
52-Week Low 14.23

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar